VIOLIN: Vaccine Investigation and Online Information Network

Tick-borne Encephalitis Virus (TBEV)

Table of Contents

General Information
Vaccine Related Pathogen Genes
1. E (Protective antigen)
2. NS1 (Protective antigen)
3. NS3 (Protective antigen)
4. TBEVgp1 polyprotein (Protective antigen)
5. C protein (Virmugen)
Vaccine Information
References

I. General Information

1. NCBI Taxonomy ID:

11084

2. Disease:

Tick-borne Encephalitis

3. Introduction

Tick-borne encephalitis virus (TBEV) is a virus of the family Flaviviridae and has three subtypes: European or Western tick-borne encephalitis virus, Siberian tick-borne encephalitis virus and Far eastern tick-borne encephalitis virus (formerly known as Russian Spring Summer encephalitis virus). TBEV causes tick-borne encephalitis, a human viral disease of the central nervous system, typically presenting in meningitis, encephalitis or meningoencephilitis. Ixodid Ticks are the vector and reservoir for TBEV, with the main hosts being rodents, with humans being accidental hosts. The disease is endemic to Europe, Russia and Asia.

II. Vaccine Related Pathogen Genes

1. C protein

Gene Name : C protein
Sequence Strain (Species/Organism) : Tick-borne encephalitis virus
NCBI Protein GI : 206570298
Other Database IDs : CDD:110034
Taxonomy ID : 11084
Gene Strand (Orientation) : ?
Protein Name : capsid protein
Protein Length : 35
Protein Note : Flavivirus capsid protein C; pfam01003

Protein Sequence : Show Sequence

>gi|206570298|gb|ACI12930.1| capsid protein [Tick-borne encephalitis virus]
MARKAILKGKGGGPPRRVSKETAKKTRQSRVQMPN

Molecule Role : Virmugen
Molecule Role Annotation : A virus with a mutation in protein C is attenuated in mice and induced protection from challenge with wild type TBE virus (Kofler et al., 2002).
Related Vaccine(s): Tick-borne Encephalitis Virus C protein mutant vaccine

2. E

Gene Name : E
Sequence Strain (Species/Organism) : Tick-borne Encephalitis Virus (TBEV)
NCBI Protein GI : CAC94472
Other Database IDs : CDD:279241
CDD:213392
CDD:213897
GOA:Q8UYS5
HSSP: 1SVB
InterPro: IPR000336
InterPro: IPR011998
InterPro: IPR011999
InterPro: IPR013755
InterPro: IPR013756
InterPro: IPR014756
UniProtKB/TrEMBL: Q8UYS5
Taxonomy ID : 11084
Protein Name : E protein
Protein pI : 7.56
Protein Weight : 42769
Protein Length : 494
Protein Note : Flavivirus glycoprotein, central and dimerization domains; pfam00869

Protein Sequence : Show Sequence

>CAC94472.1 E protein, partial [Tick-borne encephalitis virus]
TQGTTRVTLVLELGGCVTITAEGKPSMDVWLDSIYQENPAKTREYCLHAKLSDTKVAARCPTMGPAVLAE
EHQSGTVCKRDQSDRGWGNHCGLFGKGSIVTCVKAACEAKKKATGHVYDANKIVYTVKVEPHTGDYVAAN
ETHSGRKTASFTVSSEKTILNMGDYGDVSLLCRVASGVDLAQTVILELDKTLEHLPTAWQVHRDWFNDLA
LPWKHEGAQHWNNAERLVEFGAPHAVKMDVYNLGDQTGVLLKSLAGVPVAHIDGTKYHLKSGHVTCEVGL
EKLKMKGLTYTMCDKTKFTWKRTPTDSGHDTVVMEVTFSGTKPCRIPVRAVAHGSPDVNVAMLITPNPTI
ENNGGGFIEMQLPPGDNIIYVGELSHQWFQKGSSIGRVFQKTRKGIERLTVIGEHAWDFGSTGGFLTSVG
KAL

Molecule Role : Protective antigen
Molecule Role Annotation : (Stenkova et al., 2017)
Related Vaccine(s): Encepur

3. NS1

Gene Name : NS1
Sequence Strain (Species/Organism) : Tick-borne Encephalitis Virus (TBEV)
NCBI Protein GI : CAA44678
Other Database IDs : CDD:213897
CDD:279316
InterPro: IPR001157
UniProtKB/TrEMBL: Q88482
Taxonomy ID : 11084
Protein Name : unnamed
Protein pI : 6.07
Protein Weight : 38586.51
Protein Length : 441
Protein Note : flavivirus envelope glycoprotein E, stem/anchor domain; TIGR04240

Protein Sequence : Show Sequence

>CAA44678.1 NS1, partial [Tick-borne encephalitis virus]
RNPTMSMSFLLAGGLVLAMTLGVGADVGCAVDTERMELRCGEGLVVWREVSEWYDNYAYYPETPGALASA
IKETFEEGSCGVVPQNRLEMAMWRSSVTVLNLALAEGEANLTVVVDKFDPTDYRGGVSGLLRKGKDIKAS
WKSWGHSIIWSTPEAPRRFMVGTEGQSECPLERRKTGVFTVAEFGVGLRTKVFLDFRQEPTHECDTGVMG
AAVKNGMAIHTDQSLWMRSMKNDTGTYIVELLVTDLRNCSWPASHTIDNADVVDSELLLPASLAGPRSWY
NRIPGYSEQVKGPWKYTPIRVIREECPGTTVTINAKCDKRGASVRSTTESGKVIPEWCCRACTMPPVTFR
TGADCWYAMEIRPVHDQGGLVRSMVVA

Molecule Role : Protective antigen
Molecule Role Annotation : (Dmitriev et al., 1996)
Related Vaccine(s): Encepur

4. NS3

Gene Name : NS3
Sequence Strain (Species/Organism) : Tick-borne Encephalitis Virus (TBEV)
NCBI Protein GI : AGL40608
Other Database IDs : CDD:214692
CDD:284962
CDD:238005
Taxonomy ID : 11084
Protein Name : NS3
Protein pI : 9.85
Protein Weight : 22543.99
Protein Length : 271
Protein Note : genotype: European

Protein Sequence : Show Sequence

>AGL40608.1 NS3, partial [Tick-borne encephalitis virus]
GTGWTSKGQITVLDMHPGSGKTHRVLPELIRQCIDRRLRTLVLAPTRVVLKEMERALNGKRVRFHSPAVS
DQQAGGAIVDVMCHATYVNRRLLPQGRQNWEVAIMDEAHWTDPHSIAARGHLYTLAKENKCALVLMTATP
PGKSEPFPESNGAITSEERQIPDGEWRDGFDWITEYEGRTAWFVPSIAKGGAIARTLRQKGKSVICLNSK

Molecule Role : Protective antigen
Molecule Role Annotation : (Dmitriev et al., 1996)

5. TBEVgp1 polyprotein

Gene Name : TBEVgp1 polyprotein
Sequence Strain (Species/Organism) : Tick-borne encephalitis virus
VO ID : VO_0011245
NCBI Gene ID : 1489719
NCBI Protein GI : 9628432
Locus Tag : TBEVgp1
Genbank Accession : U27495
Protein Accession : NP_043135
Taxonomy ID : 11084
Gene Starting Position : 132
Gene Ending Position : 10376
Gene Strand (Orientation) : +
Protein Name : polyprotein
Protein pI : 8.16
Protein Weight : 347270.05
Protein Length : 3414

DNA Sequence : Show Sequence

>NC_001672.1:132-10376 Tick-borne encephalitis virus, complete genome
GATGGTCAAGAAGGCCATCCTGAAAGGTAAGGGGGGCGGTCCCCCTCGACGAGTGTCGAAAGAGACCGCA
ACGAAGACGCGTCAACCCAGAGTCCAAATGCCAAATGGGCTTGTGTTGATGCGCATGATGGGGATCTTGT
GGCATGCCGTAGCCGGCACCGCGAGAAACCCCGTATTGAAGGCGTTCTGGAACTCAGTCCCTCTGAAACA
GGCAACAGCAGCACTGCGGAAGATCAAAAGGACGGTGAGTGCCCTAATGGTTGGCTTGCAAAAACGTGGG
AAAAGGAGGTCAGCGACGGACTGGATGAGCTGGTTGCTGGTCATCACTCTGTTGGGGATGACGCTTGCTG
CAACGGTGAGGAAAGAAAGGGATGGCTCAACTGTGATCAGAGCTGAAGGAAAGGATGCAGCAACTCAGGT
GCGTGTGGAGAATGGCACCTGTGTGATCCTGGCTACTGACATGGGGTCATGGTGTGATGATTCACTGTCC
TATGAGTGTGTGACCATAGATCAAGGAGAAGAGCCTGTTGACGTGGATTGTTTTTGCCGGAACGTTGATG
GAGTCTATCTGGAGTACGGACGCTGTGGGAAACAGGAAGGCTCACGGACAAGGCGCTCAGTGCTGATCCC
ATCCCATGCTCAGGGAGAGCTGACGGGAAGGGGACACAAATGGCTAGAAGGAGACTCGCTGCGAACACAC
CTTACTAGAGTTGAGGGATGGGTCTGGAAGAACAAGCTACTTGCCTTGGCAATGGTTACCGTTGTGTGGT
TGACCCTGGAGAGTGTGGTGACCAGGGTTGCCGTTCTTGTTGTGCTCCTGTGTTTGGCACCGGTTTACGC
TTCGCGTTGCACACACTTGGAAAACAGGGACTTTGTGACTGGTACTCAGGGGACTACGAGGGTCACCTTG
GTGCTGGAACTGGGTGGATGTGTTACTATAACAGCTGAGGGGAAGCCTTCAATGGATGTGTGGCTTGACG
CCATTTACCAGGAGAACCCTGCTAAGACACGTGAGTACTGTTTACACGCCAAGTTGTCGGACACTAAGGT
TGCAGCCAGATGCCCAACAATGGGACCAGCCACTTTGGCTGAAGAACACCAGGGTGGCACAGTGTGTAAG
AGAGATCAGAGTGATCGAGGCTGGGGCAACCACTGTGGACTGTTTGGAAAGGGTAGCATTGTGGCCTGTG
TCAAGGCGGCTTGTGAGGCAAAAAAGAAAGCCACAGGACATGTGTACGACGCCAACAAAATAGTGTACAC
GGTCAAAGTCGAACCACACACGGGAGACTATGTTGCCGCAAACGAGACACATAGTGGGAGGAAGACGGCA
TCCTTCACAATTTCTTCAGAGAAAACCATTTTGACTATGGGTGAGTATGGAGATGTGTCTTTGTTGTGCA
GGGTCGCTAGTGGCGTTGACTTGGCCCAGACCGTCATCCTTGAGCTTGACAAGACAGTGGAACACCTTCC
AACGGCTTGGCAGGTCCATAGGGACTGGTTCAATGATCTGGCTCTGCCATGGAAACATGAGGGAGCGCAA
AACTGGAACAACGCAGAAAGACTGGTTGAATTTGGGGCTCCTCACGCTGTCAAGATGGACGTGTACAACC
TCGGAGACCAGACTGGAGTGTTACTGAAGGCTCTCGCTGGGGTTCCTGTGGCACACATTGAGGGAACCAA
GTACCACCTGAAGAGTGGCCACGTGACCTGCGAAGTGGGACTGGAAAAACTGAAGATGAAAGGTCTTACG
TACACAATGTGTGACAAAACAAAGTTCACATGGAAGAGAGCTCCAACAGACAGTGGGCATGATACAGTGG
TCATGGAAGTCACATTCTCTGGAACAAAGCCCTGTAGGATCCCAGTCAGGGCAGTGGCACATGGATCTCC
AGATGTGAACGTGGCCATGCTGATAACGCCAAACCCAACAATTGAAAACAATGGAGGTGGCTTCATAGAG
ATGCAGCTGCCCCCAGGGGATAACATCATCTATGTTGGGGAACTGAGTCATCAATGGTTCCAAAAAGGGA
GCAGCATCGGAAGGGTTTTCCAAAAGACCAAGAAAGGCATAGAAAGACTGACAGTGATAGGAGAGCACGC
CTGGGACTTCGGTTCTGCTGGAGGCTTTCTGAGTTCAATTGGGAAGGCGGTACATACGGTCCTTGGTGGC
GCTTTCAACAGCATCTTCGGGGGAGTGGGGTTTCTACCAAAACTTTTATTAGGAGTGGCATTGGCTTGGT
TGGGCCTGAACATGAGAAACCCTACAATGTCCATGAGCTTTCTCTTGGCTGGAGGTCTGGTCTTGGCCAT
GACCCTTGGAGTGGGGGCGGATGTTGGTTGCGCTGTGGACACGGAACGAATGGAGCTCCGCTGTGGCGAG
GGCCTGGTCGTGTGGAGAGAGGTCTCAGAATGGTATGACAATTATGCCTACTACCCGGAGACACCGGGGG
CCCTTGCATCAGCCATAAAGGAGACATTTGAGGAGGGAAGCTGTGGTGTAGTCCCCCAGAACAGGCTCGA
GATGGCCATGTGGAGAAGCTCGGTCACAGAGCTGAATTTGGCTCTGGCGGAAGGGGAGGCAAATCTCACA
GTGGTGGTGGACAAGTTTGACCCCACTGACTACCGAGGTGGTGTCCCTGGTTTACTGAAAAAAGGAAAGG
ACATAAAAGTCTCCTGGAAAAGCTGGGGCCATTCAATGATCTGGAGCATTCCTGAGGCCCCCCGTCGCTT
CATGGTGGGCACGGAAGGACAAAGTGAGTGTCCCCTAGAGAGACGGAAGACAGGTGTTTTCACGGTGGCA
GAATTCGGGGTTGGCCTGAGAACAAAGGTCTTCTTGGATTTCAGACAGGAACCAACACATGAGTGTGACA
CAGGAGTGATGGGAGCTGCAGTCAAGAACGGCATGGCAATCCACACAGATCAAAGTCTCTGGATGAGATC
AATGAAAAATGACACAGGCACTTACATAGTTGAACTTTTGGTCACTGACCTGAGGAACTGCTCATGGCCT
GCTAGCCACACTATCGATAATGCTGACGTGGTGGACTCAGAGTTATTCCTTCCGGCGAGCCTGGCAGGAC
CCAGATCCTGGTACAACAGGATACCTGGCTATTCAGAACAGGTGAAAGGGCCATGGAAGTACACGCCTAT
CCGAGTTATCAGAGAGGAGTGTCCCGGCACGACCGTTACCATCAACGCCAAGTGTGACAAAAGAGGAGCA
TCTGTGAGGAGTACCACAGAGAGTGGCAAGGTTATCCCAGAATGGTGCTGCCGAGCGTGCACAATGCCAC
CAGTGACGTTCCGGACTGGAACTGATTGCTGGTATGCCATGGAAATACGGCCAGTCCATGACCAGGGGGG
GCTTGTTCGCTCAATGGTGGTTGCGGACAACGGTGAATTACTTAGTGAGGGAGGAGTCCCCGGAATAGTG
GCATTGTTTGTGGTCCTTGAATACATCATCCGTAGGAGGCCCTCCACGGGAACGACGGTTGTGTGGGGGG
GTATCGTCGTTCTCGCTCTGCTTGTCACCGGGATGGTCAGGATAGAGAGCCTGGTGCGCTATGTGGTGGC
AGTGGGGATCACATTCCACCTTGAGCTGGGGCCAGAGATCGTGGCCTTGATGCTACTCCAGGCTGTGTTT
GAGCTGAGGGTGGGTTTGCTCAGCGCATTTGCATTGCGCAGAAGCCTCACCGTCCGAGAGATGGTGACCA
CCTACTTTCTTTTGCTGGTCCTGGAATTGGGGCTGCCGGGTGCGAGCCTTGAGGAGTTCTGGAAATGGGG
TGATGCACTGGCCATGGGGGCGCTGATATTCAGGGCTTGCACGGCAGAAGGAAAGACTGGAGCGGGGCTT
TTGCTCATGGCTCTCATGACACAGCAGGATGTGGTGACTGTGCACCATGGACTGGTGTGCTTCCTAAGTG
TAGCTTCGGCATGCTCGGTCTGGAGGCTGCTCAAGGGACACAGAGAGCAGAAGGGATTGACCTGGGTTGT
CCCCCTGGCTGGGTTGCTTGGGGGAGAGGGCTCTGGAATCAGACTGCTGGCGTTTTGGGAGTTGTCAGCG
CACAGAGGAAGACGATCTTTCAGTGAACCACTAACTGTGGTAGGAGTCATGCTAACACTGGCCAGCGGCA
TGATGCGACACACTTCCCAGGAGGCTCTCTGTGCACTCGCAGTGGCCTCGTTTCTCTTGCTGATGCTGGT
GCTGGGGACAAGAAAGATGCAGCTGGTTGCCGAATGGAGTGGCTGCGTTGAATGGTATCCGGAACTAGTG
AATGAGGGTGGAGAGGTTAGCCTGCGGGTCCGGCAGGACGCGATGGGTAACTTTCACTTGACTGAGCTCG
AGAAAGAAGAGAGAATGATGGCTTTTTGGCTGATTGCCGGCTTGGCAGCTTCGGCCATTCACTGGTCAGG
CATTCTTGGTGTGATGGGACTGTGGACGCTCACGGAAATGCTGAGGTCATCCCGAAGGTCTGACCTGGTT
TTCTCTGGACAGGGGGGTCGAGAGCGTGGTGACAGACCTTTCGAGGTTAAGGACGGTGTCTACAGGATTT
TTAGCCCCGGCTTGTTCTGGGGTCAGAACCAGGTGGGAGTTGGCTACGGTTCCAAGGGTGTCTTGCACAC
GATGTGGCACGTGACGAGAGGAGCGGCGCTGTCTATTGATGACGCTGTGGCCGGTCCCTACTGGGCTGAT
GTGAGGGAAGATGTCGTGTGTTACGGAGGAGCCTGGAGCCTGGAGGAAAAATGGAAAGGTGAAACAGTAC
AGGTCCATGCCTTCCCACCGGGGAGGGCGCATGAGGTGCATCAGTGCCAGCCTGGGGAGTTGATCCTTGA
CACCGGAAGAAAGCTTGGGGCAATACCAATTGATTTGGTGAAAGGAACATCAGGCAGCCCCATTCTCAAC
GCCCAGGGAGTGGTTGTGGGGCTATACGGAAATGGCCTAAAAACTAATGAGACCTACGTCAGCAGCATTG
CTCAAGGGGAAGCGGAGAAGAGTCGCCCCAACCTCCCACAGGCTGTTGTGGGTACGGGCTGGACATCAAA
GGGTCAGATCACAGTGCTGGACATGCACCCAGGCTCGGGGAAGACCCACAGAGTCCTCCCGGAGCTCATT
CGCCAATGCATTGACAGGCGCCTGAGAACGTTGGTGTTGGCTCCAACTCGTGTGGTACTCAAAGAAATGG
AGCGTGCTTTGAATGGGAAACGGGTCAGGTTCCACTCACCAGCAGTCAGTGACCAACAGGCTGGAGGGGC
AATTGTCGATGTGATGTGTCACGCAACCTATGTCAACAGAAGGCTACTCCCACAGGGAAGACAAAATTGG
GAGGTGGCAATCATGGATGAGGCCCACTGGACGGACCCCCACAGCATAGCTGCCAGAGGTCATTTGTATA
CTCTGGCAAAAGAAAACAAGTGTGCACTGGTCTTGATGACAGCGACACCTCCTGGTAAGAGTGAACCCTT
TCCGGAGTCCAATGGAGCCATTACTAGTGAGGAAAGACAGATTCCTGATGGGGAGTGGCGTGACGGGTTT
GACTGGATCACTGAGTATGAAGGGCGCACCGCCTGGTTTGTCCCTTCGATTGCAAAAGGTGGTGCTATAG
CTCGCACCTTGAGACAGAAGGGGAAAAGTGTGATTTGTTTGAACAGCAAAACCTTTGAAAAGGACTACTC
CAGAGTGAGGGATGAGAAGCCTGACTTTGTGGTGACGACTGATATCTCGGAGATGGGAGCTAACCTTGAC
GTGAGCCGCGTCATAGATGGGAGGACAAACATCAAGCCCGAGGAGGTTGATGGGAAAGTCGAGCTCACCG
GGACCAGGCGAGTGACCACGGCTTCCGCTGCCCAACGGCGCGGAAGAGTTGGTCGGCAAGACGGACGAAC
AGATGAATACATATACTCTGGACAGTGTGATGATGATGACAGTGGATTAGTGCAATGGAAAGAGGCGCAA
ATACTTCTTGACAACATAACAACCTTGCGGGGGCCCGTGGCCACCTTCTATGGACCAGAACAGGACAAGA
TGCCGGAGGTGGCCGGTCACTTTCGACTCACTGAAGAGAAAAGAAAGCACTTCCGACATCTTCTCACCCA
TTGTGACTTCACACCGTGGCTGGCATGGCACGTCGCAGCGAATGTATCCAGCGTCACGGATCGAAGCTGG
ACATGGGAAGGGCCGGAGGCAAATGCCGTGGATGAGGCCAGTGGTGACTTGGTCACCTTTAGGAGCCCGA
ATGGGGCGGAGAGAACTCTCAGGCCGGTGTGGAAGGACGCACGTATGTTCAAAGAGGGACGTGACATCAA
AGAGTTCGTGGCGTACGCGTCTGGGCGTCGCAGCTTCGGAGATGTTCTGACAGGAATGTCGGGAGTTCCT
GAGCTCCTGCGGCACAGATGCGTCAGTGCCCTGGATGTCTTCTACACGCTTATGCATGAGGAACCTGGCA
GCAGGGCAATGAGAATGGCGGAGAGAGATGCCCCAGAGGCCTTTCTGACTATGGTTGAGATGATGGTGCT
GGGTTTGGCAACCCTGGGTGTCATCTGGTGCTTCGTCGTCCGGACTTCAATCAGCCGCATGATGCTGGGC
ACGCTGGTCCTGCTGGCCTCCTTGCTACTCTTGTGGGCAGGTGGCGTCGGCTATGGGAACATGGCTGGAG
TGGCTCTCATCTTTTACACGTTGCTGACGGTGCTGCAGCCTGAGGCGGGAAAACAGAGAAGCAGTGACGA
CAACAAACTGGCATATTTCTTGCTGACGCTCTGCAGCCTTGCTGGACTGGTTGCAGCCAATGAGATGGGC
TTTCTGGAGAAGACCAAGGCAGACTTGTCCACGGCGCTGTGGAGTGAACGGGAGGAACCCCGGCCATGGA
GTGAATGGACGAATGTGGACATCCAGCCAGCGAGGTCCTGGGGGACCTATGTGCTGGTGGTGTCTCTGTT
CACACCTTACATCATCCACCAACTGCAGACCAAAATCCAACAACTTGTCAACAGTGCCGTGGCATCTGGT
GCACAGGCCATGAGAGACCTTGGGGGAGGTGCCCCCTTCTTTGGTGTGGCGGGACATGTCATGACCCTCG
GGGTGGTGTCACTGATTGGGGCTACTCCCACCTCACTGATGGTGGGCGTTGGCTTGGCGGCACTCCATCT
GGCCATTGTGGTGTCTGGTCTGGAGGCTGAATTAACACAGAGAGCTCATAAGGTCTTTTTCTCTGCAATG
GTGCGCAACCCCATGGTGGATGGGGATGTCATCAACCCATTCGGGGAGGGGGAGGCAAAACCTGCTCTAT
ATGAAAGGAAAATGAGTCTGGTGTTGGCCACAGTGTTGTGCCTCATGTCGGTGGTCATGAACCGAACGGT
GGCCTCCATAACAGAGGCTTCAGCAGTGGGACTGGCAGCAGCGGGACAGCTGCTTAGACCGGAGGCTGAC
ACGTTGTGGACGATGCCGGTTGCTTGTGGCATGAGTGGTGTGGTCAGGGGTAGCCTGTGGGGGTTTTTGC
CTCTTGGGCATAGACTCTGGCTTCGAGCCTCTGGGGGTAGGCGTGGTGGTTCTGAGGGAGACACGCTTGG
AGATCTCTGGAAGCGGAGGCTGAACAACTGCACGAGGGAGGAATTCTTTGTGTACAGGCGCACCGGCATC
CTGGAGACGGAACGTGACAAGGCTAGAGAGTTGCTCAGAAGAGGAGAGACCAATGTGGGATTGGCTGTCT
CTCGGGGCACGGCAAAGCTTGCCTGGCTTGAGGAACGCGGATATGCCACCCTCAAGGGAGAGGTGGTAGA
TCTTGGATGTGGAAGGGGCGGCTGGTCCTATTATGCGGCATCCCGACCGGCAGTCATGAGTGTCAGGGCA
TATACCATTGGTGGAAAAGGGCACGAGGCTCCAAAGATGGTAACAAGCCTGGGTTGGAACTTGATTAAAT
TCAGATCAGGAATGGACGTGTTCAGCATGCAGCCACACCGGGCTGACACTGTCATGTGTGACATCGGAGA
GAGCAGCCCAGATGCCGCTGTGGAGGGTGAGAGGACAAGGAAAGTGATACTGCTCATGGAGCAATGGAAA
AACAGGAACCCCACGGCTGCCTGTGTGTTCAAGGTGCTGGCCCCATATCGCCCAGAAGTGATAGAGGCAC
TGCACAGATTCCAACTGCAATGGGGGGGGGGTCTGGTGAGGACCCCTTTTTCAAGGAACTCCACCCATGA
GATGTATTACTCAACAGCCGTCACTGGGAACATAGTGAACTCCGTCAATGTACAGTCGAGGAAACTTTTG
GCTCGGTTTGGAGACCAGAGAGGGCCAACCAAGGTGCCTGAACTCGACCTGGGAGTTGGAACGAGGTGTG
TGGTCTTAGCTGAGGACAAGGTGAAAGAACAAGACGTACAAGAGAGGATCAGAGCGTTGCGGGAGCAATA
CAGCGAAACCTGGCATATGGACGAGGAACACCCGTACCGGACATGGCAGTACTGGGGCAGCTACCGCACG
GCACCAACCGGCTCGGCGGCGTCACTGATCAATGGGGTTGTGAAACTTCTCAGCTGGCCATGGAACGCAC
GGGAAGATGTGGTGCGCATGGCTATGACTGACACAACGGCTTTCGGACAGCAGAGAGTGTTCAAAGATAA
AGTTGACACAAAGGCACAGGAGCCTCAGCCCGGTACAAGAGTCATCATGAGAGCTGTAAATGATTGGATT
TTGGAACGACTGGCGCAGAAAAGCAAACCGCGCATGTGCAGCAGGGAAGAATTCATAGCAAAAGTGAAAT
CAAATGCAGCCTTGGGAGCTTGGTCAGATGAGCAAAACAGATGGGCAAGTGCAAGAGAGGCTGTAGAGGA
TCCTGCATTCTGGCGCCTCGTGGATGAAGAGAGAGAAAGGCACCTCATGGGGAGATGTGCGCACTGCGTG
TACAACATGATGGGCAAGAGAGAAAAGAAACTGGGAGAGTTCGGAGTGGCGAAAGGAAGTCGGGCCATTT
GGTACATGTGGCTGGGGAGTCGCTTTTTGGAGTTCGAGGCTCTTGGATTCTTGAATGAAGACCATTGGGC
CTCTAGAGAGTCCAGTGGAGCTGGAGTTGAGGGAATAAGCTTGAACTACCTGGGCTGGCACCTCAAGAAG
TTGTCAACCCTGAATGGAGGACTCTTCTATGCAGATGACACAGCTGGCTGGGACACGAAAGTTACCAATG
CAGACTTAGAGGATGAAGAACAGATCCTACGGTACATGGAGGGTGAGCACAAACAATTGGCAACCACAAT
AATGCAAAAAGCATACCATGCCAAAGTCGTGAAGGTCGCGAGGCCTTCCCGTGATGGAGGCTGCATCATG
GATGTCATCACAAGAAGAGACCAAAGAGGTTCGGGTCAGGTTGTGACCTATGCCCTTAACACCCTCACCA
ACATAAAGGTGCAATTAATCCGAATGATGGAAGGGGAAGGGGTCATAGAGGCAGCGGATGCACACAACCC
GAGACTGCTTCGAGTGGAGCGCTGGCTGAAAGAACACGGAGAAGAGCGTCTTGGAAGAATGCTCGTCAGT
GGTGACGATTGTGTGGTGAGGCCCTTGGATGACAGATTTGGCAAAGCACTTTACTTTCTGAATGACATGG
CCAAGACCAGGAAGGACATTGGGGAATGGGAGCACTCAGCCGGCTTTTCAAGCTGGGAGGAGGTACCCTT
TTGTTCACACCATTTCCACGAGCTAGTGATGAAGGATGGACGCACCCTGGTGGTGCCGTGCCGAGACCAA
GATGAACTCGTTGGGAGGGCGCGCATCTCACCGGGGTGCGGCTGGAGTGTCCGCGAGACGGCCTGCCTTT
CAAAAGCCTACGGGCAGATGTGGCTGCTGAGCTACTTCCACCGACGAGACCTGAGGACGCTCGGGCTTGC
CATTAACTCAGCAGTGCCTGCCGATTGGGTTCCTACCGGCCGCACGACGTGGAGCATTCATGCCAGTGGG
GCCTGGATGACCACAGAAGACATGCTGGACGTTTGGAACCGGGTGTGGATTCTGGACAACCCTTTCATGC
AGAACAAGGAAAGGGTCATGGAGTGGAGGGATGTTCCGTACCTCCCTAAAGCTCAGGACATGTTATGTTC
CTCCCTTGTTGGGAGGAGAGAAAGAGCAGAATGGGCCAAGAACATCTGGGGAGCGGTGGAAAAGGTGAGG
AAGATGATAGGTCCTGAAAAGTTCAAGGACTATCTCTCCTGTATGGACCGCCATGACCTGCACTGGGAGC
TCAGACTGGAGAGCTCAATAATCTA

Protein Sequence : Show Sequence

>NP_043135.1 polyprotein [Tick-borne encephalitis virus]
MVKKAILKGKGGGPPRRVSKETATKTRQPRVQMPNGLVLMRMMGILWHAVAGTARNPVLKAFWNSVPLKQ
ATAALRKIKRTVSALMVGLQKRGKRRSATDWMSWLLVITLLGMTLAATVRKERDGSTVIRAEGKDAATQV
RVENGTCVILATDMGSWCDDSLSYECVTIDQGEEPVDVDCFCRNVDGVYLEYGRCGKQEGSRTRRSVLIP
SHAQGELTGRGHKWLEGDSLRTHLTRVEGWVWKNKLLALAMVTVVWLTLESVVTRVAVLVVLLCLAPVYA
SRCTHLENRDFVTGTQGTTRVTLVLELGGCVTITAEGKPSMDVWLDAIYQENPAKTREYCLHAKLSDTKV
AARCPTMGPATLAEEHQGGTVCKRDQSDRGWGNHCGLFGKGSIVACVKAACEAKKKATGHVYDANKIVYT
VKVEPHTGDYVAANETHSGRKTASFTISSEKTILTMGEYGDVSLLCRVASGVDLAQTVILELDKTVEHLP
TAWQVHRDWFNDLALPWKHEGAQNWNNAERLVEFGAPHAVKMDVYNLGDQTGVLLKALAGVPVAHIEGTK
YHLKSGHVTCEVGLEKLKMKGLTYTMCDKTKFTWKRAPTDSGHDTVVMEVTFSGTKPCRIPVRAVAHGSP
DVNVAMLITPNPTIENNGGGFIEMQLPPGDNIIYVGELSHQWFQKGSSIGRVFQKTKKGIERLTVIGEHA
WDFGSAGGFLSSIGKAVHTVLGGAFNSIFGGVGFLPKLLLGVALAWLGLNMRNPTMSMSFLLAGGLVLAM
TLGVGADVGCAVDTERMELRCGEGLVVWREVSEWYDNYAYYPETPGALASAIKETFEEGSCGVVPQNRLE
MAMWRSSVTELNLALAEGEANLTVVVDKFDPTDYRGGVPGLLKKGKDIKVSWKSWGHSMIWSIPEAPRRF
MVGTEGQSECPLERRKTGVFTVAEFGVGLRTKVFLDFRQEPTHECDTGVMGAAVKNGMAIHTDQSLWMRS
MKNDTGTYIVELLVTDLRNCSWPASHTIDNADVVDSELFLPASLAGPRSWYNRIPGYSEQVKGPWKYTPI
RVIREECPGTTVTINAKCDKRGASVRSTTESGKVIPEWCCRACTMPPVTFRTGTDCWYAMEIRPVHDQGG
LVRSMVVADNGELLSEGGVPGIVALFVVLEYIIRRRPSTGTTVVWGGIVVLALLVTGMVRIESLVRYVVA
VGITFHLELGPEIVALMLLQAVFELRVGLLSAFALRRSLTVREMVTTYFLLLVLELGLPGASLEEFWKWG
DALAMGALIFRACTAEGKTGAGLLLMALMTQQDVVTVHHGLVCFLSVASACSVWRLLKGHREQKGLTWVV
PLAGLLGGEGSGIRLLAFWELSAHRGRRSFSEPLTVVGVMLTLASGMMRHTSQEALCALAVASFLLLMLV
LGTRKMQLVAEWSGCVEWYPELVNEGGEVSLRVRQDAMGNFHLTELEKEERMMAFWLIAGLAASAIHWSG
ILGVMGLWTLTEMLRSSRRSDLVFSGQGGRERGDRPFEVKDGVYRIFSPGLFWGQNQVGVGYGSKGVLHT
MWHVTRGAALSIDDAVAGPYWADVREDVVCYGGAWSLEEKWKGETVQVHAFPPGRAHEVHQCQPGELILD
TGRKLGAIPIDLVKGTSGSPILNAQGVVVGLYGNGLKTNETYVSSIAQGEAEKSRPNLPQAVVGTGWTSK
GQITVLDMHPGSGKTHRVLPELIRQCIDRRLRTLVLAPTRVVLKEMERALNGKRVRFHSPAVSDQQAGGA
IVDVMCHATYVNRRLLPQGRQNWEVAIMDEAHWTDPHSIAARGHLYTLAKENKCALVLMTATPPGKSEPF
PESNGAITSEERQIPDGEWRDGFDWITEYEGRTAWFVPSIAKGGAIARTLRQKGKSVICLNSKTFEKDYS
RVRDEKPDFVVTTDISEMGANLDVSRVIDGRTNIKPEEVDGKVELTGTRRVTTASAAQRRGRVGRQDGRT
DEYIYSGQCDDDDSGLVQWKEAQILLDNITTLRGPVATFYGPEQDKMPEVAGHFRLTEEKRKHFRHLLTH
CDFTPWLAWHVAANVSSVTDRSWTWEGPEANAVDEASGDLVTFRSPNGAERTLRPVWKDARMFKEGRDIK
EFVAYASGRRSFGDVLTGMSGVPELLRHRCVSALDVFYTLMHEEPGSRAMRMAERDAPEAFLTMVEMMVL
GLATLGVIWCFVVRTSISRMMLGTLVLLASLLLLWAGGVGYGNMAGVALIFYTLLTVLQPEAGKQRSSDD
NKLAYFLLTLCSLAGLVAANEMGFLEKTKADLSTALWSEREEPRPWSEWTNVDIQPARSWGTYVLVVSLF
TPYIIHQLQTKIQQLVNSAVASGAQAMRDLGGGAPFFGVAGHVMTLGVVSLIGATPTSLMVGVGLAALHL
AIVVSGLEAELTQRAHKVFFSAMVRNPMVDGDVINPFGEGEAKPALYERKMSLVLATVLCLMSVVMNRTV
ASITEASAVGLAAAGQLLRPEADTLWTMPVACGMSGVVRGSLWGFLPLGHRLWLRASGGRRGGSEGDTLG
DLWKRRLNNCTREEFFVYRRTGILETERDKARELLRRGETNVGLAVSRGTAKLAWLEERGYATLKGEVVD
LGCGRGGWSYYAASRPAVMSVRAYTIGGKGHEAPKMVTSLGWNLIKFRSGMDVFSMQPHRADTVMCDIGE
SSPDAAVEGERTRKVILLMEQWKNRNPTAACVFKVLAPYRPEVIEALHRFQLQWGGGLVRTPFSRNSTHE
MYYSTAVTGNIVNSVNVQSRKLLARFGDQRGPTKVPELDLGVGTRCVVLAEDKVKEQDVQERIRALREQY
SETWHMDEEHPYRTWQYWGSYRTAPTGSAASLINGVVKLLSWPWNAREDVVRMAMTDTTAFGQQRVFKDK
VDTKAQEPQPGTRVIMRAVNDWILERLAQKSKPRMCSREEFIAKVKSNAALGAWSDEQNRWASAREAVED
PAFWRLVDEERERHLMGRCAHCVYNMMGKREKKLGEFGVAKGSRAIWYMWLGSRFLEFEALGFLNEDHWA
SRESSGAGVEGISLNYLGWHLKKLSTLNGGLFYADDTAGWDTKVTNADLEDEEQILRYMEGEHKQLATTI
MQKAYHAKVVKVARPSRDGGCIMDVITRRDQRGSGQVVTYALNTLTNIKVQLIRMMEGEGVIEAADAHNP
RLLRVERWLKEHGEERLGRMLVSGDDCVVRPLDDRFGKALYFLNDMAKTRKDIGEWEHSAGFSSWEEVPF
CSHHFHELVMKDGRTLVVPCRDQDELVGRARISPGCGWSVRETACLSKAYGQMWLLSYFHRRDLRTLGLA
INSAVPADWVPTGRTTWSIHASGAWMTTEDMLDVWNRVWILDNPFMQNKERVMEWRDVPYLPKAQDMLCS
SLVGRRERAEWAKNIWGAVEKVRKMIGPEKFKDYLSCMDRHDLHWELRLESSII

Molecule Role : Protective antigen
Molecule Role Annotation : Series of plasmid constructs encoding different forms of the envelope glycoprotein E of the flavivirus tick-borne encephalitis virus were constructed. These included a secreted recombinant subviral particle, a secreted carboxyl-terminally truncated soluble homodimer, a nonsecreted full-length form, and an inefficiently secreted truncated form. Mice were immunized using both i.m. injection and Gene Gun-mediated application of plasmids. The functional immune response was evaluated by determining specific neutralizing and hemagglutination-inhibiting Ab activities and by challenging the mice with a lethal dose of the virus.The plasmid construct encoding a secreted subviral particle, which carries multiple copies of the protective Ag on its surface, was superior to the other constructs in terms of extent and functionality of the Ab response as well as protection against virus challenge (Aberle et al., 1999).
Related Vaccine(s): TBEV DNA vaccine encoding E protein

III. Vaccine Information

1. Encepur

a. Product Name:

GlaxoSmithKline

b. Manufacturer:

Pfizer

c. Type:

Inactivated or "killed" vaccine

d. Status:

Licensed

e. Host Species for Licensed Use:

Human

f. Antigen

Proteins of whole virus particle and viral non structural protein 1 (NS1) and E protein.(Salat et al., 2020)

g. Gene Engineering of NS1

Type: Recombinant protein preparation
Description: Inactivated
Detailed Gene Information: Click here.

h. Gene Engineering of E

Type: Recombinant protein preparation
Description: Inactivated
Detailed Gene Information: Click here.

i. Preparation

ncepur Adults vaccines were processed using filter-aided sample preparation (FASP). , protein cysteine disulfide bonds were reduced in 0.1M dithiothreitol (DTT) in 8 M urea/0.1 M Tris/HCl (pH 8.5), and 50 mM iodoacetamide was used to alkylate cysteine residues (Salat et al., 2020).

j. Immunization Route

Intramuscular injection (i.m.)

k. Description

Encepur is a -virus formalin-inactivated TBEV vaccines avaliable in the European Union and European Economic Area. Vaccination induces neutralizing antibodies directed against the main antigenic determinant of the viral particle, the E protein.(Salat et al., 2020)

2. FSME-IMMUN

a. Product Name:

Tick-borne encephalitis vaccine, inactivated

b. Tradename:

FSME-IMMUN

c. Manufacturer:

Baxter

d. Vaccine Ontology ID:

VO_0010714

e. Type:

Inactivated or "killed" vaccine

f. Status:

Licensed

g. Location Licensed:

Canada

h. Host Species for Licensed Use:

Human

i. Adjuvant:

VO ID: VO_0000127

j. Allergen:

eggs, gentamicin, neomycin, protamine sulfate

k. Immunization Route

Intramuscular injection (i.m.)

l. Storage

FSME-IMMUN should be stored between +2°C to +8°C.

m . Approved Age for Licensed Use

Adults (18 years of age and older)

3. TBEV DNA vaccine encoding E protein

a. Vaccine Ontology ID:

VO_0004154

b. Type:

DNA vaccine

c. Status:

Research

d. Gene Engineering of TBEVgp1 polyprotein

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

e. Vector:

pCMV-β (Aberle et al., 1999)

f. Immunization Route

Intramuscular injection (i.m.)

g. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Groups of 16 BALB/c mice each received primary and booster immunizations spaced 4 wk apart. Plasmids were purified and administered i.m. (100 µg/dose) or by particle bombardment with DNA-coated gold beads (2 µg/dose) using the helium-powered Helios Gene Gun delivery system. Intramuscular inoculation of DNA in saline was done as a 100-µl injection in the right quadriceps. For Gene Gun inoculation, 1.0 µg of the same DNA was coupled to 0.5 mg of 1.0-µm-diameter gold particles, as recommended by the manufacturer (Bio-Rad). DNA-coated microcarriers were delivered into the abdominal epidermis of mice using the Gene Gun at a helium pressure setting of 400 psi. Mice immunized with the commercial TBE vaccine received 0.2 ml s.c. inoculations containing 1 µg formalin-inactivated virus (FSME Immun Inject, Baxter-Immuno, Vienna, Austria) (Aberle et al., 1999).
Challenge Protocol: Mice were subsequently challenged by i.p. inoculation with 1000 LD50 of the highly mouse-pathogenic TBE virus strain Hypr. (Aberle et al., 1999).
Efficacy: The plasmid construct encoding a secreted subviral particle, which carries multiple copies of the protective Ag on its surface, was superior to the other constructs in terms of extent and functionality of the Ab response as well as protection against virus challenge (Aberle et al., 1999).

4. TBEV Virus Like Particle Vaccine

a. Type:

Virus Particle Vaccine

b. Status:

Research

c. Host Species for Licensed Use:

None

d. Host Species as Laboratory Animal Model:

Mouse

e. Antigen

Atructural (Core/prM/E) and non-structural (NS2B/NS3Pro) proteins of TBEV (Tang et al., 2023)

f. Preparation

Expi293 cells were diluted to a density of 1.5 × 106 cells/mL before transfection with pcDNA3.1-NS2B/NS3Pro and pcDNA3.1-C/prM/E at a ratio of 1:2, then the cells were cultivated at 37°C in an atmosphere of 5% CO2, with agitation at 150 rpm. For the production of VLPs, the plasmids (480 μg) were added to polyethylenimine hydrochloride (1,350 μg; Polysciences) in 10 mL of Expi293 medium and incubated for 10 min, the mixture was then added to 470 mL of cell solution. The transfected cells were harvested at 4 days post-transfection and the supernatant was collected by two successive centrifugation steps at 400 ×g for 10 min at 4°C, then 10,000 ×g for 10 min at 4°C. The proteins in the supernatant were precipitated using 8% (wt/vol) polyethylene glycol 8000 and incubated overnight at 4°C. (Tang et al., 2023)

g. Immunization Route

Intramuscular injection (i.m.)

h. Description

Virus-like particle-based vaccine co-expressing the structural (Core/prM/E) and non-structural (NS2B/NS3Pro) proteins of TBEV confers complete protection against TBEV in mice. (Tang et al., 2023)

i. Mouse Response

Vaccination Protocol: Eight-week-old male C57BL/6 mice were used for the immunization and viral neutralization experiments. The mice (n=5 per group) were immunized by twice intramuscular injections with PBS or 10 μg of VLPs.Six to eight-week-old male IFNAR-/- mice were used for immunization and challenge experiments. The mice (n=10 per group) were immunized with PBS or 10 μg of VLPs. (Tang et al., 2023)
Immune Response: The results of ELISA demonstrated that vaccination with the VLPs stimulated a high total serum IgG response, and the prime antibody response increased by 2.5-fold following boost immunization (Fig. 2C). Additionally, the antibodies elicited by the VLPs significantly neutralized both TBEV-FE and TBEV-Eu infections in BHK-21 cells, with inhibition rates reaching up to 90%. Altogether, these findings suggested that the VLPs exhibited superior immunogenicity and induced high levels of humoral immunity (IgG and NAb) against different subtypes of TBEV. (Tang et al., 2023)
Challenge Protocol: VLP-immunized IFNAR−/− mice were challenged with a lethal dose (3.2×106 PFU) of the WH2012 strain of TBEV by intramuscular injection after two weeks post-boost immunization with 10 μg VLPs. (Tang et al., 2023)
Efficacy: The infected mice displayed some abnormal behaviors, such as listlessness, circling and freezing, and all the infected mice died within 8 dpi. In contrast, immunized mice survived the challenge, and their weights did not decrease significantly. The viremia of the control group was notably high (7.9×104 TCID50/mL), with average values in the brain and intestinal tissues reaching 1.0×10^7 and 5.0×10^5 TCID50/mL, respectively. In contrast, the mice that had been immunized with the VLPs did not exhibit any neurological symptoms and the viral loads in the serum samples, brain, and intestinal tissues were negligible or undetectable. (Tang et al., 2023)

5. Tick-borne Encephalitis Virus C protein mutant vaccine

a. Vaccine Ontology ID:

VO_0004278

b. Type:

Live, attenuated vaccine

c. Status:

Research

d. Host Species as Laboratory Animal Model:

Mouse

e. Gene Engineering of C protein

Type: Gene mutation
Description: This C protein mutant is from Tick-borne encephalitis virus (Kofler et al., 2002).
Detailed Gene Information: Click here.

f. Immunization Route

subcutaneous injection

g. Mouse Response

Persistence: A C protein mutant is attenuated in mice (Kofler et al., 2002).
Efficacy: A C protein mutant induced protection in mice from challenge with wild type TBEV (Kofler et al., 2002).

IV. References

1. Aberle et al., 1999: Aberle JH, Aberle SW, Allison SL, Stiasny K, Ecker M, Mandl CW, Berger R, Heinz FX. A DNA immunization model study with constructs expressing the tick-borne encephalitis virus envelope protein E in different physical forms. Journal of immunology (Baltimore, Md. : 1950). 1999; 163(12); 6756-6761. [PubMed: 10586074].

2. CDC: TBE: CDC: Tick-borne Encephalitis [http://www.cdc.gov/ncidod/dvrd/Spb/mnpages/dispages/TBE.htm]

3. Dmitriev et al., 1996: Dmitriev IP, Khromykh AA, Ignatyev GM, Gainullina MN, Ageenko VA, Dryga SA, Vorobyeva MS, Sandakhchiev LS. Immunization with recombinant vaccinia viruses expressing structural and part of the nonstructural region of tick-borne encephalitis virus cDNA protect mice against lethal encephalitis. Journal of biotechnology. 1996; 44(1-3); 97-103. [PubMed: 8717392].

4. Kofler et al., 2002: Kofler RM, Heinz FX, Mandl CW. Capsid protein C of tick-borne encephalitis virus tolerates large internal deletions and is a favorable target for attenuation of virulence. Journal of virology. 2002; 76(7); 3534-3543. [PubMed: 11884577].

5. Stenkova et al., 2017: Stenkova AM, Chopenko NS, Davydova LA, Mazeika AN, Bystritskaya EP, Portnyagina OY, Anastyuk SD, Kulbatskii DS, Lyukmanova EN, Dolgikh DA, Kostetsky EY, Sanina NM. Engineering of Chimeric Protein Based on E Protein Domain III of Tick- Borne Encephalitis Virus and OmpF Porin of Yersinia pseudotuberculosis. Protein and peptide letters. 2017; 24(10); 974-981. [PubMed: 28741465].